Loading
Melanoma immunotherapy leader behind pembrolizumab's first trials and the science of why immunotherapy fails.
Antoni Ribas is Professor of Medicine and Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and a past president of the American Association for Cancer Research (AACR). A medical oncologist specialising in melanoma, he led the earliest pembrolizumab studies in melanoma, including KEYNOTE-001, and defined mechanisms of resistance to checkpoint blockade such as JAK1/2 and B2M loss. His papers include a New England Journal of Medicine report on mutations associated with acquired resistance to PD-1 blockade in melanoma and a Science review of cancer immunotherapy using checkpoint blockade. He is a founder of cell-therapy and TCR companies and works on PD-1, BRAF and TCR-T cell therapy.
| Title | Journal | Year |
|---|---|---|
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | New England Journal of Medicine | 2016 |
| Cancer immunotherapy using checkpoint blockade | Science | 2018 |
| Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge | Nature | 2014 |
This is the standard overview of checkpoint immunotherapy for clinicians and scientists, tying together the trial results and the biology of response and resistance that guide today's combination trials.
This paper explained why PD-1 antibodies work in some patients and not others and introduced the idea of inflamed versus non-inflamed tumours that now guides combination strategies designed to bring T cells into cold tumours.
Shares TCR-T cell therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), BRAF, PD-1, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade, Advanced melanoma (unresectable stage III and stage IV), PD-1, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), PD-1, Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.